PURACAP Trademark

Trademark Overview


On Tuesday, October 18, 2022, a trademark application was filed for PURACAP with the United States Patent and Trademark Office. The USPTO has given the PURACAP trademark a serial number of 97637140. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, October 30, 2024. This trademark is owned by PuraCap Pharmaceutical LLC. The PURACAP trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceuticals for use in treatment of seizures, hypertension, cardiovascular disease, disease of the endocrine system, gastroenterological disease, hematological disease, infectious disease, disease of the immune system, musculoskeletal disease, kidney disease, disease of the nervous system, gynecological disease, cancer, diseases of the eye, ear, nose and throat, mental illness, rheumatological disease, bone disease, skin wounds, contact dermatitis, headaches, migraine headaches, muscle pain, inflammation, and for use in dental, cosmetic, maxillofacial, and plastic surgery, all available as tablets, capsules, softgels, liquids, creams, and powders
puracap

General Information


Serial Number97637140
Word MarkPURACAP
Filing DateTuesday, October 18, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateWednesday, October 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 5, 2023

Trademark Statements


Goods and Servicespharmaceuticals for use in treatment of seizures, hypertension, cardiovascular disease, disease of the endocrine system, gastroenterological disease, hematological disease, infectious disease, disease of the immune system, musculoskeletal disease, kidney disease, disease of the nervous system, gynecological disease, cancer, diseases of the eye, ear, nose and throat, mental illness, rheumatological disease, bone disease, skin wounds, contact dermatitis, headaches, migraine headaches, muscle pain, inflammation, and for use in dental, cosmetic, maxillofacial, and plastic surgery, all available as tablets, capsules, softgels, liquids, creams, and powders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 2, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePuraCap Pharmaceutical LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressIselin, NJ 08830

Party NamePuraCap Pharmaceutical LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIselin, NJ 08830

Trademark Events


Event DateEvent Description
Friday, October 21, 2022NEW APPLICATION ENTERED
Wednesday, August 2, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 2, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 1, 2023ASSIGNED TO EXAMINER
Wednesday, August 16, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 5, 2023PUBLISHED FOR OPPOSITION
Tuesday, September 5, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 31, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 30, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, April 30, 2024SOU EXTENSION 1 FILED
Tuesday, April 30, 2024SOU EXTENSION 1 GRANTED
Wednesday, May 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 30, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 30, 2024SOU EXTENSION 2 FILED
Wednesday, October 30, 2024SOU EXTENSION 2 GRANTED